Opinion

Video

Optimizing Therapy Sequencing in CLL

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD

A panel of experts discuss optimizing therapy sequencing in CLL.

Video content above is prompted by the following question(s):

  • How do you determine the optimal sequencing of therapies for patients with CLL?
  • How does prior therapy exposure influence your choice of subsequent treatments?
Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com
May 1st 2025

Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

AJMC Contributor
Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Triple combination therapy guided by MRD showed promise in R/R CLL. | Image credit: Matthieu - stock.adobe.com
April 28th 2025

MRD-Guided Triplet Therapy Leads to Deep Remissions in R/R CLL

Jared Kaltwasser
Minimal residual disease (MRD)-guided triple therapy showed promising results for relapsed chronic lymphocytic leukemia (CLL), achieving high rates of undetectable disease and prolonged survival.
Acalabrutinib is a second-generation BTKi with reduced cardiovascular toxicity and an overall better safety profile compared with ibrutinib. | Image credit: Laszlo - stock.adobe.com
April 20th 2025

Acalabrutinib Combos Improve PFS vs CIT in First-Line CLL

AJMC Contributor
Acalabrutnib plus venetoclax, with or without obinutuzumab, improved progression-free survival (PFS) compared with chemoimmunotherapy (CIT) in patients with untreated chronic lymphocytic leukemia (CLL), meeting the phase 3 AMPLIFY study’s primary endpoint.
While pausing therapy did not affect response to vaccination, the investigators noted that participants who paused therapy did have higher rates of self-reported lymphadenopathy. | Image credit: Konstantin Yuganov - stock.adobe.com
April 18th 2025

Pausing BTK Inhibitors Does Not Strengthen COVID Vaccination in CLL

Jared Kaltwasser
Previous work had suggested pausing Bruton tyrosine kinase (BTK) inhibitors before COVID-19 vaccination might boost immunity in patients with chronic lymphocytic leukemia (CLL).
In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com
April 15th 2025

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

Jared Kaltwasser
Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo